---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-008937"
form_type: "8-K"
ticker: "BNBX"
cik: "0000744452"
company_name: "BNB PLUS CORP."
filed_at: "2024-02-01T23:59:59+00:00"
generated_at: "2026-06-06T12:13:48.668951+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Applied DNA Sciences raises ~$3.44M in registered direct offering at $0.609/share

## Summary
- Gross proceeds expected $3.44M from 5,644,061 shares (or prefunded warrants) at $0.609 each.
- Concurrent private placement: warrants for 11,288,122 shares at $0.609, exercisable upon stockholder approval, 5-year term.
- Exercise price of 3,113,213 existing outstanding warrants reduced to $0.609 and expiration extended to 2028, subject to shareholder approval.
- Net proceeds for therapeutic DNA production development and general corporate purposes; closing expected Feb 2, 2024.
- Placement agent Maxim Group LLC; lock-up on insiders for 60 days post-closing.

## SEC filing metadata
- accession: 0001104659-24-008937
- form_type: 8-K
- ticker: BNBX
- cik: 0000744452
- company_name: BNB PLUS CORP.
- filed_at: 2024-02-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744452/000110465924008937/0001104659-24-008937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744452/000110465924008937/tm244700d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-008937
- JSON: https://secwatch.observer/filing/0001104659-24-008937.json
- Plain text: https://secwatch.observer/filing/0001104659-24-008937.txt

## Key facts
- Material Agreements
  BNB PLUS CORP. entered into Purchase Agreements with certain institutional investors (effective 2024-01-31).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Effective: 2024-01-31
  source text: Also on January 31, 2024, in connection with the Offering, the Company entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional investors (each, a “Purchaser” and, collectively, the “Purchasers”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/744452/000110465924008937/0001104659-24-008937-index.htm
- Material Agreements
  BNB PLUS CORP. entered into Placement Agreement with Maxim Group LLC (effective 2024-01-31).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Maxim Group LLC
  - Effective: 2024-01-31
  source text: On January 31, 2024, Applied DNA Sciences, Inc. (“Company”) entered into a placement agency agreement (the “Placement Agreement”) with Maxim Group LLC (the “Placement Agent”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/744452/000110465924008937/0001104659-24-008937-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.